Fluoxetine Tablet, Film Coated
NDC Package 62332-243-91
Package Information
Fluoxetine tablets is when using fluoxetine and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax. . This formulation utilizes a tablet, film coated delivery system. Marketed by Alembic Pharmaceuticals Inc., this product is identified by NDC 62332-243 and is authorized under FDA application ANDA208698.
Identification & Billing
- RxCUI: 248642 - FLUoxetine 20 MG Oral Tablet
- RxCUI: 248642 - fluoxetine 20 MG Oral Tablet
- RxCUI: 248642 - fluoxetine 20 MG (as fluoxetine hydrochloride 22.4 MG) Oral Tablet
- RxCUI: 313990 - FLUoxetine HCl 10 MG Oral Tablet
- RxCUI: 313990 - fluoxetine 10 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62332 - Alembic Pharmaceuticals Inc.
- 62332-243 - Fluoxetine
- 62332-243-91 - 1000 TABLET, FILM COATED in 1 BOTTLE
- 62332-243 - Fluoxetine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (62332-243). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62332-243-91 identifies a specific commercial package of 1000 tablet, film coated in 1 bottle of Fluoxetine, a human prescription drug labeled by Alembic Pharmaceuticals Inc.. This tablet, film coated is formulated for oral use and contains fluoxetine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alembic Pharmaceuticals Inc. on April 07, 2017. The current certification is valid through December 31, 2026.
How is this Alembic Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62332024391. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.